Lifestance Health (LFST)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$12.73-0.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Lifestance grows revenue to about $1.68 billion in 2026. Profit rises with adjusted EBITDA near $220 million. Quarterly revenue and profit keep improving. The company shows steady growth and better profits.
Revenue growth could slow below 17%. Profit gains might stall or reverse. High valuation risks a price drop if growth fades.
Price is about 42% above our fair value near $7.7. Analysts expect 17% revenue growth, which is reflected in the price.
Breaks if: Adjusted EBITDA falls below $200 million in FY26
Breaks if: Quarterly revenue or operating income falls below targets
Revenue falls below $1.64 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story within the healthcare sector. The company is currently loss-making but has shown strong revenue and EBITDA growth, indicating a potential recovery phase.
The market appears to have priced in a low expectations gap, suggesting that investors are cautiously optimistic about LFST's ability to meet its growth targets. The valuation is at a premium compared to peers, reflecting some confidence in its recent performance.
Management is on track to achieve its revenue and EBITDA goals for 2026, with strong growth in both areas reported recently. However, there is a moderate risk of missing future guidance, which could impact sentiment.
The future performance of LFST hinges on maintaining its growth trajectory and the broader healthcare sector's performance. Key factors include the company's ability to meet or exceed guidance and the impact of economic conditions on the healthcare market.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The new $100 million share repurchase program aligns with the company's capital allocation strategy. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on increasing full-year revenue to a raised guidance range of $1.64 billion to $1.68 billion for fiscal 2026.
Over the next 1 to 3 years, LFST's outlook remains intact, supported by strong recent results, but it must navigate potential risks. Not investment advice.